

Review

Jumonji C Demethylases in Cellular Senescence

Kelly E. Leon  and Katherine M. Aird *Department of Cellular & Molecular Physiology, Penn State College of Medicine, Hershey, PA 17033, USA;
kleon2@pennstatehealth.psu.edu

* Correspondence: kaird@psu.edu

Received: 13 November 2018; Accepted: 3 January 2019; Published: 9 January 2019



Abstract: Senescence is a stable cell cycle arrest that is either tumor suppressive or tumor promoting depending on context. Epigenetic changes such as histone methylation are known to affect both the induction and suppression of senescence by altering expression of genes that regulate the cell cycle and the senescence-associated secretory phenotype. A conserved group of proteins containing a Jumonji C (JmjC) domain alter chromatin state, and therefore gene expression, by demethylating histones. Here, we will discuss what is currently known about JmjC demethylases in the induction of senescence, and how these enzymes suppress senescence to contribute to tumorigenesis.

Keywords: epigenetics; cell cycle; metabolism; histones; senescence-associated secretory phenotype; senescence-associated heterochromatin foci; p53; retinoblastoma protein

1. Introduction

Chromatin is organized through nucleosomes, which contain an octamer core of wrapped DNA [1,2]. This octamer core consists of two copies of each core histone, H2A, H2B, H3, and H4 [2,3]. Core histones are primarily identified by their histone fold domain and their N-terminal tails [4]. Interestingly, histone tails undergo various post-translational modifications such as acetylation, methylation, phosphorylation, ubiquitination, and others [5,6]. These various modifications can result in gene expression alterations through changes in electrostatic charge, which alters DNA accessibility [7].

A common histone modification that can result in changes to gene expression is methylation, a reversible post-translational modification [8,9]. Histone methylation occurs on lysine, arginine, and histidine residues, resulting in transcriptional activation or silencing of genes, the recruitment of DNA damage response proteins, and changes in chromosomal packaging and DNA accessibility [10,11]. Through the recruitment of various enzymes, such as histone methyltransferases (HMTs) and histone demethylases, the methylation state of a particular histone can be altered. HMTs have been extensively reviewed elsewhere [12]. Here, we will focus on a conserved group of histone demethylases containing a Jumonji C (JmjC) domain [8,13,14]. JmjC demethylases are oxygenases dependent on Fe(II) and α -ketoglutarate (α KG) for their activity [8,13,15,16]. Histone demethylation through JmjC proteins occurs through a hydroxylation reaction, in which α KG, oxygen, and Fe(II) are used to produce succinate and CO₂ [12,13,15]. This hydroxylation reaction results in unstable hemiaminal products, which are broken into formaldehyde and a demethylated histone product [13,15]. Twenty-four human enzymes are currently known to contain a JmjC domain and have histone demethylase activity [17]. These enzymes are organized into subfamilies based on sequence homology and methylation state preference [17,18].

JmjC histone demethylases regulate chromatin state through the removal of mono-, di-, and trimethylation marks on the lysine residues of multiple histones [19]. Changes within the chromatin state can lead to either activation or repression of transcription, depending on the amino acid residue

that is targeted. Additionally, methylation changes may also affect other cellular processes, such as DNA damage repair, without affecting transcription of surrounding genes [20,21]. Consistently, JmjC demethylases play a role in various pathological conditions [17,22]. For instance, JmjC demethylases have been shown to be both pro-tumorigenic and tumor suppressive [23,24]. This is due in part to their activity in inducing and suppressing senescence, a stable cell cycle arrest that is primarily mediated by the tumor suppressors p53 and pRb (retinoblastoma protein) [25,26]. Here we will discuss the role of JmjC demethylases in senescence in the context of suppressing or promoting tumorigenesis.

2. Role of Jumonji C Demethylases in Senescence

A number of studies have shown a role for JmjC demethylases in senescence. Here, we will discuss what is known about these enzymes (specifically KDM6B, KDM5A, KDM5B, KDM4A, KDM4B, and KDM2B) in regulating the senescence phenotype (Table 1).

Table 1. Jumonji C (JmjC) histone demethylases play a role in inducing and suppressing cellular senescence.

JmjC Histone Demethylase	Target(s)	Implications in Senescence	Role in Suppressing Senescence to Promote Tumorigenesis
KDM6B	H3K27me3/2 H3K9me2/1 H4K20me1	Overexpression increases SASP gene expression [27]; promotes SAHF formation through pRb [28]; regulation of p53 [29]	Overexpressed in glioma cells to promote SASP expression [27]
KDM5B	H3K4me3/2	Silences E2F target genes [30,31]; knockdown increases H3K4 methylation at the <i>CDKN2A</i> locus [30]	
KDM5A	H3K4me3/2	Knockdown or depletion induces senescence by increasing p21, p27, p16 [32,33]	Expression is required in pRb-defective cancer [34]
KDM4A	H3K36me3/2 H3K9me3/2	Downregulation activates the p53 pathway and induces PML body accumulation [35]	Cooperates with RAS to promote transformation [35]; affects the SASP [36]
KDM4B	H3K36me3/2 H3K9me3/2	No direct evidence; p53-responsive [37,38]; important for DSB repair [38,39]	
KDM2B	H3K36me2/1 H3K4me3 H3K79me3/2	Demethylates <i>CDKN2A</i> [40] and <i>CDKN2B</i> loci [41]	Cooperates with KRAS to promote pancreatic cancer [42]; immortalizes MEFs [24,40]

SAHF: senescence-associated heterochromatin foci; SASP: senescence-associated secretory phenotype; pRb: retinoblastoma protein; DSB: double-stranded break.

2.1. Cellular Senescence

Cellular senescence is defined as a stable cell cycle arrest [25]. Senescence can occur due to a variety of stimuli, including oncogenic stress [26,43]. Therefore, senescence is considered a tumor suppression mechanism [44]. Two canonical tumor suppressor pathways play a role in maintaining cells in the senescence-associated cell cycle arrest, p53/p21 and p16/pRb [26,45]. Senescent cells have a marked change in their epigenome, in part through increased repressive histone modifications, in particular H3K9me3/2 [46]. This along with other changes in the chromatin structure of senescent cells is called senescence-associated heterochromatin foci (SAHF) [46,47]. Increased repressive H3K9me3/2 is observed at proliferation-promoting E2F gene targets such as *CCNA2*, *PCNA*, *MCM3*, and *DHFR* [48]. This inhibits transcription of these genes and in part promotes the senescence phenotype [46,48].

In addition to SAHF, senescent cells also acquire a unique microenvironment known as the senescence-associated secretory phenotype (SASP). SASP gene transcription is increased during senescence, resulting in an increase in cytokines, chemokines, and matrix metalloproteinases (MMPs) in the senescent microenvironment [28,49]. The increase in inflammatory cytokines due to the SASP can have detrimental side effects resulting in chronic inflammation and tumorigenesis [49,50]. In contrast, the SASP contributes to the clearance of senescent cells, thereby limiting tumorigenesis [51]. JmjC

demethylases have been shown to affect both the SAHF and SASP during senescence (Figure 1), which will be addressed in detail below.




Figure 1. Senescence pathways regulated by JmjC demethylases. The five JmjC demethylases shown are known to affect senescence through the p16/pRb pathway, the p53/p21 pathway, or the senescence-associated secretory phenotype. KDM6B, KDM5B, KDM5A, KDM4A, and KDM2B have all been shown to regulate *CDKN2A*, which feeds into the pRb pathway. Additional JmjC demethylases (KDM6B, KDM5B, and KDM5A) directly regulate pRb. Multiple enzymes regulate the p53/p21 pathway to induce senescence, including KDM6B, KDM5B, and KDM5A. Finally, KDM4A and KDM6B regulate the SASP.

2.2. *KDM6B*

KDM6B demethylates the repressive mark lysine 27 on histone H3 (H3K27me₃) [52]. *KDM6B* is important for multiple senescent phenotypes, including SASP gene expression, p16 expression, SAHF, and p53 expression [27–29,53]. Overexpression of *KDM6B* increases SASP gene expression in glioma cell lines [27]. Consistently, H3K27 methylation is lost at SASP gene loci, suggesting that H3K27 methylation suppresses SASP gene expression under normal conditions. In addition to increasing SASP gene expression, other studies have demonstrated that *KDM6B* expression increases during cellular senescence, and this may in part help maintain the *CDKN2A* locus (encoding p14^{ARF} and p16^{INK4A}) in a demethylated and activated state [29,53]. Moreover, *KDM6B* demethylates retinoblastoma protein (pRb), which inhibits its interaction with cyclin-dependent kinase 4 (CDK4) and reduces pRb phosphorylation formation [28]. pRb is known to play a role in SAHF formation [46]. Therefore, *KDM6B* promotes SAHF formation through demethylating pRb. Finally, *KDM6B* regulates p53 by binding to p53-responsive promoter and enhancer elements upon DNA damage [29]. Although the mechanism is not clear, it is interesting to speculate that *KDM6B* is necessary at those loci to remove H3K27 methylation so that DNA damage response genes are not repressed. In this context, *KDM6B* expression may allow for cells to overcome DNA damage-induced senescence. Therefore, further work needs to be performed to fully understand whether *KDM6B* is tumor suppressive or tumor promoting. Together, these findings suggest that *KDM6B* is important for multiple senescence pathways. It will be interesting in the future to determine whether *KDM6B* activity acts in concert at multiple loci during senescence to affect this phenotype.

2.3. *KDM5B*

KDM5B, also known as *JARID1B*, demethylates lysine 4 on histone H3 (H3K4me), an active histone mark [54]. Two distinct methods for induction of senescence through *KDM5B* activity have been described. Upon knockdown of *KDM5B*, colorectal cancer (CRC) cells have increased H3K4 methylation at the *CDKN2A* locus [30]. This correlates with decreased proliferation and increased

senescence-associated- β -galactosidase (SA- β -Gal) activity, a marker of senescence [30,55]. Additionally, KDM5B, through a direct interaction with pRb, promotes H3K4me3/2 demethylation in a model of oncogene-induced senescence, which results in the silencing of E2F target gene promoters [31]. Consistently, overexpression of KDM5B decreased H3K4 methylation and proliferation-promoting E2F gene targets and increased senescence. Together, these two studies demonstrate that H3K4 methylation is important for proliferation-promoting gene expression to suppress senescence, and modulation of H3K4 demethylase KDM5B affects both expression of these genes and the senescence-associated cell cycle arrest.

Additionally, many reports indicate that the demethylase activity of KDM5B is critical for DNA damage repair and genomic instability [56–58]. Indeed, inhibition or knockdown of KDM5B activates p53 and inhibits cell proliferation [56,57], hallmarks of senescence. Therefore, it is possible that cells with KDM5B knockdown are undergoing senescence due to an alteration in the DNA damage response. Future work will need to determine the role of KDM5B loss in the DNA damage accumulation observed during senescence.

2.4. KDM5A

Similar to KDM5B, KDM5A (JARID1A/RBP2), demethylates H3K4me3/2 [13]. KDM5A binds to pRb to modulate transcription downstream of pRb [59]. Knockdown of KDM5A induces senescence through an increase in cyclin-dependent kinase inhibitors such as p21, p27, and p16 in multiple cell types through increased H3K4me3 occupancy at the promoters of these genes [32,33]. pRb is critical for SAHF formation during senescence [46]. Thus, future studies are needed to determine the role of KDM5A–pRb binding in SAHF formation.

2.5. KDM4A

KDM4A demethylates H3K9me2 and H3K9me3, two repressive histone marks [60]. Additionally, the co-crystal structures of KDM4A suggest KDM4A also recognizes and binds to H3K4me3/2 and H3K20me3/2 active and repressive marks, respectively [61,62]. Downregulation of KDM4A activates the p53 pathway, thereby inducing senescence [35]. Specifically, loss of KDM4A increases repressive H3K9me3 at the promoter region of chromodomain helicase DNA binding protein 5 (*CHD5*), resulting in transcriptional repression of *CHD5* [63]. This in turn upregulates p53 levels to induce senescence. In addition, knockdown of KDM4A induces an accumulation of promyelocytic leukemia (PML) bodies [35]. PML bodies, a marker of senescence, regulate SASP gene expression and fuse with persistent DNA damage foci termed DNA segments with chromatin alterations reinforcing senescence (DNA-SCARS) [64,65]. While the authors did not investigate the role of KDM4A on SASP gene expression, it is possible that the loss of KDM4A may also affect transcription of these genes through the active H3K4 histone mark. Another study found that KDM4A forms a complex with F-box protein 22 (FBXO22) to target methylated p53 for ubiquitin-mediated degradation [36]. Consistent with the study by Mallette et al., this study showed that depletion of KDM4A upregulates p53 expression and induces senescence. Interestingly, this study also found that the FBXO22–KDM4A complex is necessary for p16 and SASP induction in late-stage senescence. However, a role for KDM4A as a histone demethylase in this context is unclear. Finally, microRNAs have been shown to regulate *KDM4A* gene expression by binding to its 3' UTR. In particular, miR-10a has been shown to bind and repress *KDM4A*, resulting in growth arrest of prostate cancer cells [66]. Additionally, decreased KDM4A expression, mediated through miR-137, leads to an induction of senescence through the p53 and pRb pathway. However, it is unknown whether this is through histone demethylation or other mechanisms. Together, these studies demonstrate that KDM4A expression and activity are important for both p53 and p16 expression and that inhibition of KDM4A induces senescence.

2.6. KDM4B

Similar to KDM4A, KDM4B also demethylates H3K9me3 [67]. Although it has not been shown to directly affect the induction of senescence, KDM4B is in part regulated by p53 [37,38], a critical senescence modulator [25]. *KDM4B* expression is activated upon p53 binding to its promoter region [63]. When this occurs, p53 no longer efficiently activates the expression of its downstream targets *p21*, *PIG3*, and *PUMA*. Interestingly, KDM4B was not recruited to the promoters of *p21*, *PIG3*, or *PUMA*, and H3K9me3 remained high at these loci. Further work will be needed to elucidate how KDM4B is indirectly affecting the DNA damage response downstream of p53. Additionally, KDM4B is important for repair of DNA double strand breaks [38,39], and knockdown of KDM4B inhibits proliferation of cancer cells after induction of DNA damage [38]. Together, these data may explain why KDM4B is high in cancer cells [68], to limit the effects of p53 and promote DNA repair to overcome or bypass senescence.

2.7. KDM2B

KDM2B is a conserved nuclear protein that demethylates both active histone marks (H3K4me3, H3K36me2, and H3K79me3/2) and the repressive histone mark H3K27me3 [69]. Multiple studies have demonstrated that KDM2B demethylates H3K4me3 and H3K36me2 at the *CDKN2A* and *CDKN2B* loci [40,41]. Consistently, increased KDM2B immortalizes MEFs [24,40]. Recent work identified KDM2B as the histone demethylase for H3K79. A deficiency in DOT1L, the H3K79 histone methyltransferase, induces senescence [70]. Future work will need to determine whether KDM2B affects this mark during senescence. Together, these studies emphasize the critical role of KDM2B in gene silencing and preventing cellular senescence.

Overall, JmjC demethylases play a role in cellular senescence by targeting proteins involved in one of the two major tumor suppressive pathways involved in maintaining cells in a senescence-associated cell cycle arrest, namely p16 and p53. As cellular senescence is both beneficial and detrimental, further investigations into how JmjC demethylases affect senescence and especially the SASP will be essential for understanding whether these enzymes can be targeted for therapeutic purposes to inhibit or eliminate senescent cells.

3. Jumonji C Histone Demethylases Suppress Senescence during Tumorigenesis

3.1. Jumonji C Demethylases Affect Cell Cycle Regulatory Genes to Suppress Senescence

As discussed above, senescence is defined as a stable cell cycle arrest [25]. Therefore, it is thought to be a bona fide tumor suppressor mechanism, and overcoming senescence is a critical barrier in tumorigenesis in some tumors [71,72]. Numerous JmjC demethylases are associated with tumorigenesis through a role in suppressing senescence (Table 1). This is mostly due to modulation of cell cycle-related genes and the p53 pathway, as detailed below.

KDM5B and KDM5A are highly expressed in cancer [73,74]. However, only KDM5A has been shown to play a role in suppressing senescence during tumorigenesis. As mentioned above, KDM5A binds to pRb to promote senescence [59]. In Rb-null tumors, KDM5A ablation prolongs survival of mice, which correlates with increased H3K4me3 [34]. While the authors did not show that KDM5A overexpression induces tumorigenesis, it is interesting to speculate that increased KDM5A activity alone may overcome senescence.

KDM2B is overexpressed in multiple cancer types [75]. In regards to suppressing senescence, KDM2B expression plays a role in pancreatic cancer tumorigenesis by bypassing KRAS^{G12D}-mediated senescent lesions (pancreatic intraepithelial neoplasia) [42]. Additionally, Kdm2b expression immortalizes MEFs by suppressing replicative senescence through inhibition of both the pRb and p53 pathways [24]. This suggests that KDM2B may play a role in tumorigenesis through inhibiting these two critical tumor suppressor pathways. Interestingly, KDM2B expression alone is not able to suppress

replicative senescence in human cells, suggesting that it cannot protect cells from telomere erosion [24]. Finally, KDM2B cooperates with HRAS^{G12V} to facilitate transformation of MEFs [41].

KDM4A cooperates with RAS to promote transformation through suppression of the p53 pathway [35]. It is possible that KDM4A is necessary to suppress senescence as it is highly expressed or amplified in a number of human cancers [68,76,77]. Together, it is clear that some JmjC demethylases are critically important for suppressing senescence. Future work will need to determine the specificity of the JmjC demethylase and its downstream targets during tumorigenesis.

3.2. JmjC Demethylases Affect the Senescence-Associated Secretory Phenotype

In addition to the cell cycle arrest, senescence is also often defined by the SASP [78]. The SASP can be tumor suppressive or tumor promoting, depending on the context [49]. Although the SASP can result in the clearance of tumorigenic cells through an immune response [51], it can also promote tumorigenesis through its detrimental side effects [49]. For instance, the SASP can induce epithelial-mesenchymal transition (EMT), mediated primarily through the increase in IL-6 and IL-8 [78,79]. In addition, the SASP increases angiogenesis through vascular endothelial growth factor (VEGF) expression [80]. Finally, the SASP can promote chemotherapy resistance [49]. As some JmjC demethylases affect SASP gene expression, it is possible that these demethylases contribute to tumorigenesis by promoting chronic inflammation. For instance, KDM6B overexpression in glioma cells increases SASP gene expression, leading to tumorigenesis and tumor progression [27]. Additionally, KDM4A is necessary for the SASP as knockdown of KDM4A in combination with RAS expression inhibits *IL6* and *IL8* expression [36].

As more research comes to light about histone methylation in DNA damage repair and gene transcription of the SASP and cell cycle regulators, in addition to non-histone targets of JmjC demethylases, we will undoubtedly learn more about their roles in tumorigenesis.

4. Targeting JmjC Demethylases for Cancer Therapy

As we have discussed here, epigenetic histone modifications affect both physiological and pathological processes. In particular, cancer progression is associated with numerous epigenetic modifications. Histone demethylation can change the chromatin state, leading to the enhancement or repression of gene expression [81,82]. In the context of cancer, histone demethylation of tumor suppressor gene loci can result in gene activation and promote tumorigenesis. Thus, there has been an increased interest in developing small molecule inhibitors that target JmjC demethylases [83,84], which we will discuss below.

Recent studies have identified *N*-oxalylglycine, an analog of α KG that competitively binds at the active site of JmjC demethylases [84]. High-throughput screens indicate *N*-oxalylglycine is a KDM4E inhibitor [85]. Inhibiting KDM4E, which is often overexpressed in breast, lung, and prostate tumors, may therefore have a positive impact in cancer repression. Although *N*-oxalylglycine inhibits KDM4E, it is not an ideal compound because of its high polarity and its ability to bind to other iron (II) and α KG-dependent enzymes [86]. Therefore, it is likely to have toxicity to normal cells.

In search for an alternative to *N*-oxalylglycine, a potent inhibitor, *N*-oxalyl-D-tyrosine was found to inhibit KDM4 and KDM5 subfamilies. *N*-oxalyl-D-tyrosine is a derivative of D-tyrosine and binds to the active site of KDM4 and KDM5 subfamilies, which does not allow for α KG to bind and activate the enzymes [87]. KDM4 and KDM5 are overexpressed in various cancers and downregulate tumor suppressors. This subfamily of JmjC demethylases are amplified in lymphomas and regulate the function of the MYC oncogene in neuroblastomas [88,89]. As previously mentioned, members of the KDM5 subfamily are overexpressed in prostate cancer, thereby promoting tumorigenesis. Overall, the KDM4 and KDM5 subfamilies can be considered proto-oncogenes. Therefore, targeting these JmjC demethylases could potentially result in tumor suppression. In addition to *N*-oxalyl-D-tyrosine, pyridine dicarboxylic acids were found to completely bind to the same active site as *N*-oxalyl-D-tyrosine in KDM4 subfamilies [90]. The use of pyridine dicarboxylic acids as JmjC demethylase inhibitors has

also been shown to reduce proliferation in different cancer cell lines [91]. NCDM-32B, a KDM4 small molecule inhibitor, has also been shown to reduce cell viability and anchorage-independent growth in breast cancer cell lines through regulation of multiple cancer pathways [92]. Finally, PKF118-310 is a specific KDM4A inhibitor [93]. Although the interaction between KDM4A and PKF118-310 induces apoptosis of multiple tumor types, the exact binding site is unknown. Further work on these compounds will be necessary to determine the on-target toxicity and specificity for certain JmjC demethylases.

More recently, 5-carboxy-8-hydroxyquinoline (IOX1) has been shown to inhibit a broad spectrum of JmjC demethylases by binding at the α KG binding pocket [94]. Although IOX1 directly binds the α KG binding pocket to affect JmjC demethylase activity, it also chelates iron (II), which may produce negative effects on iron-dependent proteins [94]. Additionally, the pyridine hydrazine derived from aryl *N*-heteroaryl ketones, JIB-04, has also been shown to inhibit a broad spectrum of JmjC demethylases [95,96]. Unlike IOX1, JIB-04 does not completely bind to the α KG binding pocket, but instead interacts with iron at the catalytic site [96]. Although it does not bind at the α KG binding pocket, JIB-04 still chelates iron (II) when the iron concentration is higher than 400 nM. Compared to other JmjC demethylase inhibitors that bind at the α KG binding pocket, JIB-04 tends to be more specific for JmjC histone demethylase family members as it does not interact with prolyl hydroxylases (PHDs), which require α KG for their activity [96,97]

Although numerous histone demethylase inhibitors have been characterized, they are not specific to one JmjC demethylase. Current inhibitors target JmjC demethylases by affecting the ability of α KG or iron (II) binding. The search for a histone demethylase inhibitor with higher potency and selectivity is still undergoing extensive research. Moreover, as many JmjC demethylases have multiple histone, and potentially non-histone targets, it will be important to further investigate the on-target toxicity of these inhibitors.

5. Conclusions

In summary, JmjC demethylases have been shown to play a role in various cancers, having both tumorigenic and tumor suppressive roles. In particular, studies have demonstrated that JmjC demethylases affect senescence and may promote tumorigenesis through suppressing the senescence-associated cell cycle arrest or activating the SASP. Interestingly, although known as histone demethylases, studies have shown that these enzymes may affect senescence through other non-histone-mediated pathways. Nevertheless, the upregulation of these enzymes in many cancers makes them a promising therapeutic target. Future work to develop more selective inhibitors and to determine on-target side effects will be necessary to delineate the therapeutic potential of inhibiting these enzymes in cancer.

Author Contributions: Conceptualization, K.E.L. and K.M.A.; writing—original draft preparation, K.E.L. and K.M.A.; writing—review and editing, K.E.L. and K.M.A.; funding acquisition, K.M.A.

Funding: This research was funded by the National Institutes of Health (R00CA194309) and the W. W. Smith Charitable Trust to K.M.A.

Acknowledgments: We would like to thank the members of the Aird lab for their thoughtful comments. K.E.L. is supported by the Biomedical Sciences Graduate Program at Pennsylvania State College of Medicine.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Davey, C.A.; Sargent, D.F.; Luger, K.; Maeder, A.W.; Richmond, T.J. Solvent mediated interactions in the structure of the nucleosome core particle at 1.9 Å resolution. *J. Mol. Biol.* **2002**, *319*, 1097–1113. [[CrossRef](#)]
2. Luger, K.; Mader, A.W.; Richmond, R.K.; Sargent, D.F.; Richmond, T.J. Crystal structure of the nucleosome core particle at 2.8 Å resolution. *Nature* **1997**, *389*, 251–260. [[CrossRef](#)] [[PubMed](#)]

3. Kornberg, R.D.; Thomas, J.O. Chromatin structure; oligomers of the histones. *Science* **1974**, *184*, 865–868. [[CrossRef](#)] [[PubMed](#)]
4. Arents, G.; Moudrianakis, E.N. The histone fold: A ubiquitous architectural motif utilized in DNA compaction and protein dimerization. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 11170–11174. [[CrossRef](#)] [[PubMed](#)]
5. Kebede, A.F.; Schneider, R.; Daujat, S. Novel types and sites of histone modifications emerge as players in the transcriptional regulation contest. *FEBS J.* **2015**, *282*, 1658–1674. [[CrossRef](#)] [[PubMed](#)]
6. Kouzarides, T. Chromatin modifications and their function. *Cell* **2007**, *128*, 693–705. [[CrossRef](#)] [[PubMed](#)]
7. Fenley, A.T.; Anandakrishnan, R.; Kidane, Y.H.; Onufriev, A.V. Modulation of nucleosomal DNA accessibility via charge-altering post-translational modifications in histone core. *Epigenet. Chromatin* **2018**, *11*, 11. [[CrossRef](#)] [[PubMed](#)]
8. Shi, Y.; Lan, F.; Matson, C.; Mulligan, P.; Whetstone, J.R.; Cole, P.A.; Casero, R.A.; Shi, Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. *Cell* **2004**, *119*, 941–953. [[CrossRef](#)]
9. Schneider, J.; Shilatifard, A. Histone demethylation by hydroxylation: Chemistry in action. *ACS Chem. Biol.* **2006**, *1*, 75–81. [[CrossRef](#)]
10. Byvoet, P.; Shepherd, G.R.; Hardin, J.M.; Noland, B.J. The distribution and turnover of labeled methyl groups in histone fractions of cultured mammalian cells. *Arch. Biochem. Biophys.* **1972**, *148*, 558–567. [[CrossRef](#)]
11. Li, T.; Vu, T.H.; Ulaner, G.A.; Yang, Y.; Hu, J.F.; Hoffman, A.R. Activating and silencing histone modifications form independent allelic switch regions in the imprinted *Gnas* gene. *Hum. Mol. Genet.* **2004**, *13*, 741–750. [[CrossRef](#)] [[PubMed](#)]
12. Marmorstein, R.; Trievel, R.C. Histone modifying enzymes: Structures, mechanisms, and specificities. *Biochim. Biophys. Acta* **2009**, *1789*, 58–68. [[CrossRef](#)] [[PubMed](#)]
13. Accari, S.L.; Fisher, P.R. Emerging roles of JmjC domain-containing proteins. *Int. Rev. Cell Mol. Biol.* **2015**, *319*, 165–220. [[CrossRef](#)] [[PubMed](#)]
14. Takeuchi, T.; Yamazaki, Y.; Katoh-Fukui, Y.; Tsuchiya, R.; Kondo, S.; Motoyama, J.; Higashinakagawa, T. Gene trap capture of a novel mouse gene, *jumonji*, required for neural tube formation. *Genes Dev.* **1995**, *9*, 1211–1222. [[CrossRef](#)] [[PubMed](#)]
15. Markolovic, S.; Leissing, T.M.; Chowdhury, R.; Wilkins, S.E.; Lu, X.; Schofield, C.J. Structure-function relationships of human JmjC oxygenases-demethylases versus hydroxylases. *Curr. Opin. Struct. Biol.* **2016**, *41*, 62–72. [[CrossRef](#)] [[PubMed](#)]
16. Markolovic, S.; Wilkins, S.E.; Schofield, C.J. Protein hydroxylation catalyzed by 2-oxoglutarate-dependent oxygenases. *J. Biol. Chem.* **2015**, *290*, 20712–20722. [[CrossRef](#)] [[PubMed](#)]
17. Labbe, R.M.; Holowatyj, A.; Yang, Z.Q. Histone lysine demethylase (KDM) subfamily 4: Structures, functions and therapeutic potential. *Am. J. Transl. Res.* **2013**, *6*, 1–15. [[PubMed](#)]
18. Rotili, D.; Mai, A. Targeting histone demethylases: A new avenue for the fight against cancer. *Genes Cancer* **2011**, *2*, 663–679. [[CrossRef](#)]
19. Cloos, P.A.; Christensen, J.; Agger, K.; Helin, K. Erasing the methyl mark: Histone demethylases at the center of cellular differentiation and disease. *Genes Dev.* **2008**, *22*, 1115–1140. [[CrossRef](#)]
20. Loughery, J.E.; Dunne, P.D.; O'Neill, K.M.; Meehan, R.R.; McDaid, J.R.; Walsh, C.P. DNMT1 deficiency triggers mismatch repair defects in human cells through depletion of repair protein levels in a process involving the DNA damage response. *Hum. Mol. Genet.* **2011**, *20*, 3241–3255. [[CrossRef](#)]
21. Jin, B.; Robertson, K.D. DNA methyltransferases, DNA damage repair, and cancer. *Adv. Exp. Med. Biol.* **2013**, *754*, 3–29. [[CrossRef](#)] [[PubMed](#)]
22. De Santa, F.; Totaro, M.G.; Prosperini, E.; Notarbartolo, S.; Testa, G.; Natoli, G. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. *Cell* **2007**, *130*, 1083–1094. [[CrossRef](#)] [[PubMed](#)]
23. Dalglish, G.L.; Furge, K.; Greenman, C.; Chen, L.; Bignell, G.; Butler, A.; Davies, H.; Edkins, S.; Hardy, C.; Latimer, C.; et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. *Nature* **2010**, *463*, 360–363. [[CrossRef](#)] [[PubMed](#)]
24. Pfau, R.; Tzatsos, A.; Kampranis, S.C.; Serebrennikova, O.B.; Bear, S.E.; Tschlis, P.N. Members of a family of JmjC domain-containing oncoproteins immortalize embryonic fibroblasts via a JmjC domain-dependent process. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 1907–1912. [[CrossRef](#)] [[PubMed](#)]

25. Campisi, J. Cellular senescence as a tumor-suppressor mechanism. *Trends Cell Biol.* **2001**, *11*, S27–S31. [[CrossRef](#)]
26. Dimri, G.P. What has senescence got to do with cancer? *Cancer Cell* **2005**, *7*, 505–512. [[CrossRef](#)] [[PubMed](#)]
27. Perrigue, P.M.; Silva, M.E.; Warden, C.D.; Feng, N.L.; Reid, M.A.; Mota, D.J.; Joseph, L.P.; Tian, Y.I.; Glackin, C.A.; Gutova, M.; et al. The histone demethylase jumonji coordinates cellular senescence including secretion of neural stem cell-attracting cytokines. *Mol. Cancer Res.* **2015**, *13*, 636–650. [[CrossRef](#)] [[PubMed](#)]
28. Zhao, L.; Zhang, Y.; Gao, Y.; Geng, P.; Lu, Y.; Liu, X.; Yao, R.; Hou, P.; Liu, D.; Lu, J.; et al. JMJD3 promotes SAHF formation in senescent WI38 cells by triggering an interplay between demethylation and phosphorylation of RB protein. *Cell Death Differ.* **2015**, *22*, 1630–1640. [[CrossRef](#)]
29. Williams, K.; Christensen, J.; Rappsilber, J.; Nielsen, A.L.; Johansen, J.V.; Helin, K. The histone lysine demethylase JMJD3/KDM6B is recruited to p53 bound promoters and enhancer elements in a p53 dependent manner. *PLoS ONE* **2014**, *9*, e96545. [[CrossRef](#)] [[PubMed](#)]
30. Ohta, K.; Haraguchi, N.; Kano, Y.; Kagawa, Y.; Konno, M.; Nishikawa, S.; Hamabe, A.; Hasegawa, S.; Ogawa, H.; Fukusumi, T.; et al. Depletion of JARID1B induces cellular senescence in human colorectal cancer. *Int. J. Oncol.* **2013**, *42*, 1212–1218. [[CrossRef](#)]
31. Chicas, A.; Kapoor, A.; Wang, X.; Aksoy, O.; Everitts, A.G.; Zhang, M.Q.; Garcia, B.A.; Bernstein, E.; Lowe, S.W. H3K4 demethylation by Jarid1a and Jarid1b contributes to retinoblastoma-mediated gene silencing during cellular senescence. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 8971–8976. [[CrossRef](#)] [[PubMed](#)]
32. Liang, X.; Zeng, J.; Wang, L.; Fang, M.; Wang, Q.; Zhao, M.; Xu, X.; Liu, Z.; Li, W.; Liu, S.; et al. Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212. *PLoS ONE* **2013**, *8*, e69784. [[CrossRef](#)] [[PubMed](#)]
33. Zeng, J.; Ge, Z.; Wang, L.; Li, Q.; Wang, N.; Bjorkholm, M.; Jia, J.; Xu, D. The histone demethylase RBP2 is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. *Gastroenterology* **2010**, *138*, 981–992. [[CrossRef](#)] [[PubMed](#)]
34. McBrayer, S.K.; Olenchock, B.A.; DiNatale, G.J.; Shi, D.D.; Khanal, J.; Jennings, R.B.; Novak, J.S.; Oser, M.G.; Robbins, A.K.; Modiste, R.; et al. Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, E3741–E3748. [[CrossRef](#)] [[PubMed](#)]
35. Mallette Frédérick, A.; Richard, S. JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5. *Cell Rep.* **2012**, *2*, 1233–1243. [[CrossRef](#)] [[PubMed](#)]
36. Johmura, Y.; Sun, J.; Kitagawa, K.; Nakanishi, K.; Kuno, T.; Naiki-Ito, A.; Sawada, Y.; Miyamoto, T.; Okabe, A.; Aburatani, H.; et al. SCF^{Fbxo22}-KDM4A targets methylated p53 for degradation and regulates senescence. *Nat. Commun.* **2016**, *7*, 10574. [[CrossRef](#)] [[PubMed](#)]
37. Castellini, L.; Moon, E.J.; Razorenova, O.V.; Krieg, A.J.; von Eyben, R.; Giaccia, A.J. KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage. *Nucleic Acids Res.* **2017**, *45*, 3674–3692. [[CrossRef](#)] [[PubMed](#)]
38. Zheng, H.; Chen, L.; Pledger, W.J.; Fang, J.; Chen, J. p53 promotes repair of heterochromatin DNA by regulating JMJD2b and SUV39H1 expression. *Oncogene* **2014**, *33*, 734–744. [[CrossRef](#)]
39. Young, L.C.; McDonald, D.W.; Hendzel, M.J. Kdm4b histone demethylase is a DNA damage response protein and confers a survival advantage following γ -irradiation. *J. Biol. Chem.* **2013**, *288*, 21376–21388. [[CrossRef](#)]
40. Tzatsos, A.; Pfau, R.; Kampranis, S.C.; Tsiichlis, P.N. Ndy1/KDM2B immortalizes mouse embryonic fibroblasts by repressing the Ink4a/Arf locus. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 2641–2646. [[CrossRef](#)]
41. He, J.; Kallin, E.M.; Tsukada, Y.; Zhang, Y. The H3K36 demethylase Jhdmlb/Kdm2b regulates cell proliferation and senescence through p15(Ink4b). *Nature Struct. Mol. Biol.* **2008**, *15*, 1169–1175. [[CrossRef](#)] [[PubMed](#)]
42. Tzatsos, A.; Paskaleva, P.; Ferrari, F.; Deshpande, V.; Stoykova, S.; Contino, G.; Wong, K.K.; Lan, F.; Trojer, P.; Park, P.J.; et al. KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. *J. Clin. Investig.* **2013**, *123*, 727–739. [[CrossRef](#)] [[PubMed](#)]
43. Serrano, M.; Lin, A.W.; McCurrach, M.E.; Beach, D.; Lowe, S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell* **1997**, *88*, 593–602. [[CrossRef](#)]
44. Campisi, J. Aging, cellular senescence and cancer. *Annu. Rev. Physiol.* **2013**, *75*, 685–705. [[CrossRef](#)] [[PubMed](#)]
45. Haferkamp, S.; Tran, S.L.; Becker, T.M.; Scurr, L.L.; Kefford, R.F.; Rizos, H. The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence. *Aging* **2009**, *1*, 542–556. [[CrossRef](#)]

46. Narita, M.; Nunez, S.; Heard, E.; Narita, M.; Lin, A.W.; Hearn, S.A.; Spector, D.L.; Hannon, G.J.; Lowe, S.W. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. *Cell* **2003**, *113*, 703–716. [[CrossRef](#)]
47. Zhang, R.; Chen, W.; Adams, P.D. Molecular dissection of formation of senescence-associated heterochromatin foci. *Mol. Cell. Biol.* **2007**, *27*, 2343–2358. [[CrossRef](#)]
48. Chandra, T.; Kirschner, K.; Thuret, J.Y.; Pope, B.D.; Ryba, T.; Newman, S.; Ahmed, K.; Samarajiwa, S.A.; Salama, R.; Carroll, T.; et al. Independence of repressive histone marks and chromatin compaction during senescent heterochromatic layer formation. *Mol. Cell* **2012**, *47*, 203–214. [[CrossRef](#)]
49. Coppe, J.P.; Desprez, P.Y.; Krtolica, A.; Campisi, J. The senescence-associated secretory phenotype: The dark side of tumor suppression. *Annu. Rev. Pathol.* **2010**, *5*, 99–118. [[CrossRef](#)]
50. Freund, A.; Orjalo, A.V.; Desprez, P.Y.; Campisi, J. Inflammatory networks during cellular senescence: Causes and consequences. *Trends Mol. Med.* **2010**, *16*, 238–246. [[CrossRef](#)]
51. Krizhanovsky, V.; Yon, M.; Dickins, R.A.; Hearn, S.; Simon, J.; Miething, C.; Yee, H.; Zender, L.; Lowe, S.W. Senescence of activated stellate cells limits liver fibrosis. *Cell* **2008**, *134*, 657–667. [[CrossRef](#)] [[PubMed](#)]
52. Hong, S.; Cho, Y.W.; Yu, L.R.; Yu, H.; Veenstra, T.D.; Ge, K. Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 18439–18444. [[CrossRef](#)] [[PubMed](#)]
53. Agherbi, H.; Gaussmann-Wenger, A.; Verthuy, C.; Chasson, L.; Serrano, M.; Djabali, M. Polycomb mediated epigenetic silencing and replication timing at the *INK4a/ARF* locus during senescence. *PLoS ONE* **2009**, *4*, e5622. [[CrossRef](#)] [[PubMed](#)]
54. Dey, B.K.; Stalker, L.; Schnerch, A.; Bhatia, M.; Taylor-Papadimitriou, J.; Wynder, C. The histone demethylase KDM5b/JARID1b plays a role in cell fate decisions by blocking terminal differentiation. *Mol. Cell. Biol.* **2008**, *28*, 5312–53127. [[CrossRef](#)] [[PubMed](#)]
55. Dimri, G.P.; Lee, X.; Basile, G.; Acosta, M.; Scott, G.; Roskelley, C.; Medrano, E.E.; Linskens, M.; Rubelj, I.; Pereira-Smith, O.; et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 9363–9367. [[CrossRef](#)] [[PubMed](#)]
56. Bayo, J.; Tran, T.A.; Wang, L.; Pena-Llopis, S.; Das, A.K.; Martinez, E.D. Jumonji inhibitors overcome radioresistance in cancer through changes in H3K4 methylation at double-strand breaks. *Cell Rep.* **2018**, *25*, 1040–1050.E5. [[CrossRef](#)] [[PubMed](#)]
57. Li, X.; Liu, L.; Yang, S.; Song, N.; Zhou, X.; Gao, J.; Yu, N.; Shan, L.; Wang, Q.; Liang, J.; et al. Histone demethylase KDM5B is a key regulator of genome stability. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 7096–7101. [[CrossRef](#)] [[PubMed](#)]
58. Xu, W.; Zhou, B.; Zhao, X.; Zhu, L.; Xu, J.; Jiang, Z.; Chen, D.; Wei, Q.; Han, M.; Feng, L.; et al. KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance. *Int. J. Biol. Sci.* **2018**, *14*, 1122–1132. [[CrossRef](#)] [[PubMed](#)]
59. Klose, R.J.; Yan, Q.; Tothova, Z.; Yamane, K.; Erdjument-Bromage, H.; Tempst, P.; Gilliland, D.G.; Zhang, Y.; Kaelin, W.G., Jr. The retinoblastoma binding protein RBP2 is an H3K4 demethylase. *Cell* **2007**, *128*, 889–900. [[CrossRef](#)]
60. Klose, R.J.; Yamane, K.; Bae, Y.; Zhang, D.; Erdjument-Bromage, H.; Tempst, P.; Wong, J.; Zhang, Y. The transcriptional repressor JHD3A demethylates trimethyl histone H3 lysine 9 and lysine 36. *Nature* **2006**, *442*, 312–316. [[CrossRef](#)]
61. Huang, Y.; Fang, J.; Bedford, M.T.; Zhang, Y.; Xu, R.M. Recognition of histone H3 lysine-4 methylation by the double tudor domain of JMJD2A. *Science* **2006**, *312*, 748–751. [[CrossRef](#)] [[PubMed](#)]
62. Upadhyay, A.K.; Judge, R.A.; Li, L.; Pithawalla, R.; Simanis, J.; Bodelle, P.M.; Marin, V.L.; Henry, R.F.; Petros, A.M.; Sun, C. Targeting lysine specific demethylase 4A (KDM4A) tandem TUDOR domain—A fragment based approach. *Bioorg. Med. Chem. Lett.* **2018**, *28*, 1708–1713. [[CrossRef](#)] [[PubMed](#)]
63. Guerra-Calderas, L.; Gonzalez-Barrios, R.; Patino, C.C.; Alcaraz, N.; Salgado-Albarran, M.; de Leon, D.C.; Hernandez, C.C.; Sanchez-Perez, Y.; Maldonado-Martinez, H.A.; De la Rosa-Velazquez, I.A.; et al. CTCF-KDM4A complex correlates with histone modifications that negatively regulate CHD5 gene expression in cancer cell lines. *Oncotarget* **2018**, *9*, 17028–17042. [[CrossRef](#)]
64. Baar, M.P.; Brandt, R.M.C.; Putavet, D.A.; Klein, J.D.D.; Derks, K.W.J.; Bourgeois, B.R.M.; Stryeck, S.; Rijksen, Y.; van Willigenburg, H.; Feijtel, D.A.; et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. *Cell* **2017**, *169*, 132–147. [[CrossRef](#)] [[PubMed](#)]

65. Rodier, F.; Munoz, D.P.; Teachenor, R.; Chu, V.; Le, O.; Bhaumik, D.; Coppe, J.P.; Campeau, E.; Beausejour, C.M.; Kim, S.H.; et al. DNA-SCARS: Distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. *J. Cell Sci.* **2011**, *124*, 68–81. [[CrossRef](#)] [[PubMed](#)]
66. Mu, H.; Xiang, L.; Li, S.; Rao, D.; Wang, S.; Yu, K. MiR-10a functions as a tumor suppressor in prostate cancer via targeting KDM4A. *J. Cell. Biochem.* **2018**. [[CrossRef](#)] [[PubMed](#)]
67. Whetstine, J.R.; Nottke, A.; Lan, F.; Huarte, M.; Smolnikov, S.; Chen, Z.; Spooner, E.; Li, E.; Zhang, G.; Colaiacovo, M.; et al. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. *Cell* **2006**, *125*, 467–481. [[CrossRef](#)]
68. Young, L.C.; Hendzel, M.J. The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpression. *Biochem. Cell Biol.* **2013**, *91*, 369–377. [[CrossRef](#)] [[PubMed](#)]
69. He, J.; Nguyen, A.T.; Zhang, Y. KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. *Blood* **2011**, *117*, 3869–3880. [[CrossRef](#)] [[PubMed](#)]
70. Kim, W.; Kim, R.; Park, G.; Park, J.W.; Kim, J.E. Deficiency of H3K79 histone methyltransferase Dot1-like protein (DOT1L) inhibits cell proliferation. *J. Biol. Chem.* **2012**, *287*, 5588–5599. [[CrossRef](#)]
71. Bartkova, J.; Rezaei, N.; Liontos, M.; Karakaidos, P.; Kletsas, D.; Issaeva, N.; Vassiliou, L.V.; Kolettas, E.; Niforou, K.; Zoumpourlis, V.C.; et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. *Nature* **2006**, *444*, 633–637. [[CrossRef](#)] [[PubMed](#)]
72. Michaloglou, C.; Vredeveld, L.C.; Soengas, M.S.; Denoyelle, C.; Kulman, T.; van der Horst, C.M.; Majoor, D.M.; Shay, J.W.; Mooi, W.J.; Peeper, D.S. BRAFE600-associated senescence-like cell cycle arrest of human naevi. *Nature* **2005**, *436*, 720–724. [[CrossRef](#)] [[PubMed](#)]
73. Harmeyer, K.M.; Facompre, N.D.; Herlyn, M.; Basu, D. JARID1 histone demethylases: Emerging targets in cancer. *Trends Cancer* **2017**, *3*, 713–725. [[CrossRef](#)]
74. Plch, J.; Hrabeta, J.; Eckschlager, T. KDM5 demethylases and their role in cancer cell chemoresistance. *Int. J. Cancer* **2018**. [[CrossRef](#)] [[PubMed](#)]
75. Yan, M.; Yang, X.; Wang, H.; Shao, Q. The critical role of histone lysine demethylase KDM2B in cancer. *Am. J. Transl. Res.* **2018**, *10*, 2222–2233.
76. Guerra-Calderas, L.; Gonzalez-Barrios, R.; Herrera, L.A.; Cantu de Leon, D.; Soto-Reyes, E. The role of the histone demethylase KDM4A in cancer. *Cancer Genet.* **2015**, *208*, 215–224. [[CrossRef](#)]
77. Berry, W.L.; Janknecht, R. KDM4/JMJD2 histone demethylases: Epigenetic regulators in cancer cells. *Cancer Res.* **2013**, *73*, 2936–2942. [[CrossRef](#)] [[PubMed](#)]
78. Coppe, J.P.; Patil, C.K.; Rodier, F.; Sun, Y.; Munoz, D.P.; Goldstein, J.; Nelson, P.S.; Desprez, P.Y.; Campisi, J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. *PLoS Biol.* **2008**, *6*, 2853–2868. [[CrossRef](#)]
79. Laberge, R.M.; Awad, P.; Campisi, J.; Desprez, P.Y. Epithelial-mesenchymal transition induced by senescent fibroblasts. *Cancer Microenviron. Off. J. Int. Cancer Microenviron. Soc.* **2012**, *5*, 39–44. [[CrossRef](#)] [[PubMed](#)]
80. Coppe, J.P.; Kauser, K.; Campisi, J.; Beausejour, C.M. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. *J. Biol. Chem.* **2006**, *281*, 29568–29574. [[CrossRef](#)] [[PubMed](#)]
81. Lachner, M.; Jenuwein, T. The many faces of histone lysine methylation. *Curr. Opin. Cell Biol.* **2002**, *14*, 286–298. [[CrossRef](#)]
82. Silva, J.; Mak, W.; Zvetkova, I.; Appanah, R.; Nesterova, T.B.; Webster, Z.; Peters, A.H.; Jenuwein, T.; Otte, A.P.; Brockdorff, N. Establishment of histone h3 methylation on the inactive X chromosome requires transient recruitment of Eed-Enx1 polycomb group complexes. *Dev. Cell* **2003**, *4*, 481–495. [[CrossRef](#)]
83. Culhane, J.C.; Wang, D.; Yen, P.M.; Cole, P.A. Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. *J. Am. Chem. Soc.* **2010**, *132*, 3164–3176. [[CrossRef](#)]
84. Rose, N.R.; McDonough, M.A.; King, O.N.; Kawamura, A.; Schofield, C.J. Inhibition of 2-oxoglutarate dependent oxygenases. *Chem. Soc. Rev.* **2011**, *40*, 4364–4397. [[CrossRef](#)]
85. Lee, M.G.; Wynder, C.; Schmidt, D.M.; McCafferty, D.G.; Shiekhhattar, R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. *Chem. Biol.* **2006**, *13*, 563–567. [[CrossRef](#)]
86. Ivan, M.; Haberberger, T.; Gervasi, D.C.; Michelson, K.S.; Gunzler, V.; Kondo, K.; Yang, H.; Sorokina, I.; Conaway, R.C.; Conaway, J.W.; et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 13459–13464. [[CrossRef](#)]

87. Szewczuk, L.M.; Culhane, J.C.; Yang, M.; Majumdar, A.; Yu, H.; Cole, P.A. Mechanistic analysis of a suicide inactivator of histone demethylase LSD1. *Biochemistry* **2007**, *46*, 6892–6902. [[CrossRef](#)]
88. Agger, K.; Miyagi, S.; Pedersen, M.T.; Kooistra, S.M.; Johansen, J.V.; Helin, K. Jmjd2/Kdm4 demethylases are required for expression of *Il3ra* and survival of acute myeloid leukemia cells. *Genes Dev.* **2016**, *30*, 1278–1288. [[CrossRef](#)]
89. Yang, J.; Altahan, A.M.; Hu, D.; Wang, Y.; Cheng, P.H.; Morton, C.L.; Qu, C.; Nathwani, A.C.; Shohet, J.M.; Fotsis, T.; et al. The role of histone demethylase KDM4B in Myc signaling in neuroblastoma. *J. Natl. Cancer Inst.* **2015**, *107*, djv080. [[CrossRef](#)]
90. Hillringhaus, L.; Yue, W.W.; Rose, N.R.; Ng, S.S.; Gileadi, C.; Loenarz, C.; Bello, S.H.; Bray, J.E.; Schofield, C.J.; Oppermann, U. Structural and evolutionary basis for the dual substrate selectivity of human KDM4 histone demethylase family. *J. Biol. Chem.* **2011**, *286*, 41616–41625. [[CrossRef](#)]
91. Mackeen, M.M.; Kramer, H.B.; Chang, K.H.; Coleman, M.L.; Hopkinson, R.J.; Schofield, C.J.; Kessler, B.M. Small-molecule-based inhibition of histone demethylation in cells assessed by quantitative mass spectrometry. *J. Proteome Res.* **2010**, *9*, 4082–4092. [[CrossRef](#)]
92. Ye, Q.; Holowatyj, A.; Wu, J.; Liu, H.; Zhang, L.; Suzuki, T.; Yang, Z.Q. Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer. *Am. J. Cancer Res.* **2015**, *5*, 1519–1530.
93. Franci, G.; Sarno, F.; Nebbioso, A.; Altucci, L. Identification and characterization of PKF118-310 as a KDM4A inhibitor. *Epigenetics* **2017**, *12*, 198–205. [[CrossRef](#)]
94. Schiller, R.; Scozzafava, G.; Tumber, A.; Wickens, J.R.; Bush, J.T.; Rai, G.; Lejeune, C.; Choi, H.; Yeh, T.L.; Chan, M.C.; et al. A cell-permeable ester derivative of the JmJc histone demethylase inhibitor IOX1. *ChemMedChem* **2014**, *9*, 566–571. [[CrossRef](#)]
95. Easmon, J.; Heinisch, G.; Purstinger, G.; Langer, T.; Osterreicher, J.K.; Grunicke, H.H.; Hofmann, J. Azinyl and diazinyl hydrazones derived from aryl *N*-heteroaryl ketones: Synthesis and antiproliferative activity. *J. Med. Chem.* **1997**, *40*, 4420–4425. [[CrossRef](#)]
96. Wang, L.; Chang, J.; Varghese, D.; Dellinger, M.; Kumar, S.; Best, A.M.; Ruiz, J.; Bruick, R.; Pena-Llopis, S.; Xu, J.; et al. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. *Nat. Commun.* **2013**, *4*, 2035. [[CrossRef](#)]
97. Cascella, B.; Lee, S.G.; Singh, S.; Jez, J.M.; Mirica, L.M. The small molecule JIB-04 disrupts O2 binding in the Fe-dependent histone demethylase KDM4A/JMJ2A. *Chem. Commun.* **2017**, *53*, 2174–2177. [[CrossRef](#)]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).